Product information
From Health Canada
No match found
No other product was found from this company.
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2024-07-02
Original market date: See footnote 1
2018-12-07
Product name:
XERMELO
DIN:
02481553
Product Monograph/Veterinary Labelling:
Date:
2023-01-11
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
SERB SAS
40 Avenue George V
Paris
--
France
75008
Class:
Human
Dosage form(s):
Tablet
Route(s) of administration:
Oral
Number of active ingredient(s):
1
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
56:08.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
A16AX15 TELOTRISTAT
Active ingredient group (AIG) number:See footnote5
0160731001
Active ingredient(s) See footnote8 | Strength |
---|---|
TELOTRISTAT ETHYL (TELOTRISTAT ETIPRATE) | 250 MG |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.